

# Fracture Associated Metalwork Infection in Adults - Microbiology Summary Clinical Guideline

Reference number: CG-ANTI/2023/063

Clinical concerns re FAMI

No clinical concerns regarding sepsis

## Investigation

- Microbiology:
  - ± Blood cultures × 2 (e.g. if episode[s] of fever)
  - MRSA screen
- Blood sciences:
  - FBC, ESR, CRP, U&Es, and LFTs
- ± Radiology:
  - XR/US/CT may reveal suggestive criteria; however, no imaging modality reveals criteria diagnostic of FAMI

## Treatment

- Collaborate with the orthopaedic team regarding:
  - Removal versus retention of the metalwork

## Investigation

- Microbiology:
  - Biopsy/Aspirates: 6 tissues/fluids for MC&S
- Histology:
  - Biopsies: ≥ 2 tissues for histopathology

## Treatment

- Empiric, intravenous antibiotics (please note, page 2)

Clinical concerns regarding sepsis

## Investigation

- Microbiology:
  - Blood cultures × 2
  - MRSA screen
- Blood sciences:
  - FBC, ESR, CRP, lactate, U&Es, and LFTs
- ± Radiology:
  - XR/US/CT may reveal suggestive criteria; however, no imaging modality reveals criteria diagnostic of FAMI

## Treatment

- Empiric, intravenous antibiotics (please note, page 2)

## Treatment

- Collaborate with the orthopaedic team regarding:
  - Removal versus retention of the metalwork

## Investigation

- Microbiology:
  - Biopsy/Aspirates: 6 tissues/fluids for MC&S
- Histology:
  - Biopsies: ≥ 2 tissues for histopathology

Directed antibiotics with culture and susceptibilities (please note, microbiology full clinical guideline, pages 4-6)

## Empiric, intravenous antibiotics

First line	Piperacillin tazobactam 4.5 g 6 hourly <b>and</b> Vancomycin or teicoplanin, <a href="#">dose as per hospital guidelines</a> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l
Second line, <a href="#">if non-immediate without systemic involvement penicillin allergy</a>	Ceftazidime 2 g 8 hourly <b>and</b> Vancomycin or teicoplanin, <a href="#">dose as per hospital guidelines</a> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l
Third line, <a href="#">if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy</a>	Ciprofloxacin 400 mg 8 hourly <b>and</b> Vancomycin or teicoplanin, <a href="#">dose as per hospital guidelines</a> , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l

## References

- Bennett, J. E., Dolin, R., and Blaser, M. J.** 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8<sup>th</sup> Edition. Elsevier.
- emc.** 2022. Available at: <https://www.medicines.org.uk/emc/>.
- Grayson, M. L., Crowe, S. M., McCarthy, J. S., Mills, J., Mouton, J. W., Norrby, S. R., Paterson, D. L., and Pfaller, M. A.** 2010. Kucers' The Use Of Antibiotics, 6<sup>th</sup> Edition. CRC Press.
- Li, H. -K., Rombach, I., Zambellas, R., Walker, A. S., McNally, M. A., Atkins, B. L., Lipsky, B. A., Hughes, H. C., Bose, D., Kumin, M., Scarborough, C., Matthews, P. C., Brent, A. J., Lomas, J., Gundle, R., Rogers, M., Taylor, A., Angus, B., Byren, I., Berendt, A. R., Warren, S., Fitzgerald, F. E., Mack, D. J. F., Hopkins, S., Folb, J., Reynolds, H. E., Moore, E., Marshall, J., Jenkins, N., Moran, C. E., Woodhouse, A. F., Stafford, S., Seaton, R. A., Vallance, C., Hemsley, C. J., Bisnauthsing, K., Sandoe, J. A. T., Aggarwal, I., Ellis, S. C., Bunn, D. J., Sutherland, R. K., Barlow, G., Cooper, C., Geue, C., McMeekin, N., Briggs, A. H., Sendi, P., Khatamzas, E., Wangrangsimakul, T., Wong, T. H. N., Barrett, L. K., Alvand, A., Old, C. F., Bostock, J., Paul, J., Cooke, G., Thwaites, G. E., Bejon, P., and Scarborough, M.** 2019. Oral versus Intravenous Antibiotics for Bone and Joint Infection. The New England Journal of Medicine.
- Metsemakers, W. J., Morgenstern, M., McNally, M. A., Moriarty, T. F., McFadyen, I., Scarborough, M., Athanasou, N. A., Ochsner, P. E., Kuehl, R., Raschke, M., Borens, O., Xie, Z., Velkes, S., Hungerer, S., Kates, S. L., Zalavras, C., Giannoudis, P. V., Richards, R. G., and Verhofstad, M. H. J.** 2018. Fracture-related infection: A consensus on definition from an international expert group. Injury.
- Sanford Guide Antimicrobial Therapy.** 2022. Available at: <https://www.sanfordguide.com/products/digital-subscriptions/>.
- Zimmerli, W.** 2021. Bone and Joint Infections, 2<sup>nd</sup> Edition. WILEY Blackwell.

## Document control

<b>Development of guidelines:</b>	Kayleigh Lehal, Dr Peter Slovak
<b>Consultation with:</b>	Lead Antimicrobial Pharmacist, Microbiology Consultant
<b>Version:</b>	3
<b>Approval date:</b>	Antimicrobial Stewardship Group on 31/01/2023 and by Surgical division 24/01/2023
<b>Changes from previous version:</b>	Introduction: reworded (minor) and reformatted (minor). Suggestive and diagnostic criteria. Investigation: reworded (minor) and reformatted (major). Treatment: reworded (minor) and reformatted (minor). Management: reworded (minor) and reformatted (major). References: updated (minor).
<b>Date uploaded:</b>	01/03/2023
<b>Next review date:</b>	01/03/2026
<b>Key contacts:</b>	Dr Peter Slovak, Microbiology Consultant <a href="mailto:p.slovak@nhs.net">p.slovak@nhs.net</a> Kayleigh Lehal, Lead Antimicrobial Pharmacist <a href="mailto:kayleigh.lehal@nhs.net">kayleigh.lehal@nhs.net</a>